eslicarbazepine acetate has been researched along with Pain in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Micov, A; Pecikoza, U; Stepanović-Petrović, R; Tomić, M; Vuković, M | 1 |
| Micov, A; Pecikoza, U; Stepanović-Petrović, R; Tomić, M | 1 |
2 other study(ies) available for eslicarbazepine acetate and Pain
| Article | Year |
|---|---|
Eslicarbazepine acetate interacts in a beneficial manner with standard and alternative analgesics to reduce trigeminal nociception.
Topics: Acetaminophen; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Dibenzazepines; Male; Metoclopramide; Mice; Nociception; Pain; Pain Measurement; Rats, Sprague-Dawley; Stress, Psychological; Trigeminal Nerve Diseases | 2020 |
Eslicarbazepine acetate reduces trigeminal nociception: Possible role of adrenergic, cholinergic and opioid receptors.
Topics: Adrenergic Antagonists; Analgesics; Animals; Atropine; Cholinergic Antagonists; Dibenzazepines; Formaldehyde; Male; Mice; Naloxone; Narcotic Antagonists; Pain; Receptors, Adrenergic; Receptors, Cholinergic; Receptors, Opioid; Trigeminal Neuralgia; Yohimbine | 2018 |